UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) January 9, 2020

 

BIONOVATE TECHNOLOGIES CORP.

(Exact name of registrant as specified in its charter)

 

Nevada

 

333-188152

 

33-1229553

(State or other jurisdiction
of incorporation)

 

(Commission
File Number)

 

(IRS Employer
Identification No.)

 

Rothschild Blvd 22, Tel Aviv-Yafo, Israel

6688218

(Address of principal executive offices)

(Zip Code)

 

Registrant s telephone number, including area code: (280) 231-1606

 

N/A

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 ( 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ( 240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

None

None

None

 

 
 
 
 

 

Item 8.01 Other Events 

 

Further to our Current Report on Form 8-K filed on October 1, 2019, a majority of our shareholders approved a reverse stock split on a basis of 100 old shares for one (1) new share of our issued and outstanding common stock. No fractional shares of common stock will be issued as a result of the reverse split. Any fractional shares that would have resulted from the reverse split will be rounded up to the next whole number.

 

As a result of the reverse split, our issued and outstanding shares of common stock will decrease from 15,579,749 to 155,798 shares of common stock. We confirm that our authorized capital will remain unchanged.

 

The reverse split has been reviewed by the Financial Industry Regulatory Authority (FINRA) and has been approved for filing with an effective date of January 9, 2020.

 

The reverse split will become effective with the OTC Markets at the opening of trading on January 9, 2020. Our trading symbol will change to BIIOD. The "D" will be removed in 20 business days and the symbol will revert back to BIIO.  Our new CUSIP number is 09074V202.

 

 
 
 
 

  

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

BIONOVATE TECHNOLOGIES CORP.

/s/ Cohen Mizrahi

Cohen Mizrahi

President

Date: January 9, 2020

 

3

 

Bionovate Technologies (CE) (USOTC:BIIO)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Bionovate Technologies (CE) Charts.
Bionovate Technologies (CE) (USOTC:BIIO)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Bionovate Technologies (CE) Charts.